Determination of Left Ventricular Ejection Fraction Using Cardiac Angioscintigraphy
NCT ID: NCT02869308
Last Updated: 2016-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-01-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary purposes are:
* To evaluate the influence of cardiac activity recorded by D-SPECT camera on equivalences defined in primary purpose
* To evaluate the influence of the indication for the examination with a distinct analysis of a group having the examination for a known or suspected cardiomyopathy (LVEF often abnormally low) and a group having the examination for a chemotherapy supervision with heart initially considered healthy (LVEF often normal).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hand Injected Ventriculography vs. Power Injected Left Ventriculography
NCT01310517
Echocardiography in Cardiac Resynchronization Therapy (Echo-CRT)
NCT02986633
Continuous Monitoring of Right Ventricular Function, Based on the Correlation Between the C-X Segment of the Central Venous Pressure Curve, and the Echocardiographic Evaluation of Right Ventricular Systolic Function
NCT03295669
A Novel Automated & Comprehensive Approach for Ventricular Function Assessment in Heart Failure
NCT02791126
Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography
NCT00001740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These new cameras allow a better image quality than conventional Anger cameras (better spatial resolution and energy) and their detection sensitivity is almost 10 times higher. However, these new cameras can record only 3D images whereas with conventional cameras angioscintigraphy is usually performed in bidimensional way with a possible higher precision and reproducibility of LVEF measurement.
In this study, patients needing the routine examination for LVEF measurements will undergo the conventional examination followed by examination with semiconductor camera (without supplementary injection).
If LVEF measurement with semiconductor camera will be as precise and reproducible as with conventional camera, angioscintigraphy could be performed with these new cameras with a lower body irradiation of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myocardial angioscintigraphy
stannous pyrophosphate
Injection of 1ml Angiocis
Technetium-99m
Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
E-CAM Camera
Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
CZT Semiconductor Camera (D-SPECT)
Acquisition of images of angioscintigraphy with D-SPECT camera
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
stannous pyrophosphate
Injection of 1ml Angiocis
Technetium-99m
Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
E-CAM Camera
Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
CZT Semiconductor Camera (D-SPECT)
Acquisition of images of angioscintigraphy with D-SPECT camera
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Without guardianship, signed informed consent
* Not in life-and-death emergency and with a stable clinical state
* Affiliated to social security
* Preliminary medical examination
Exclusion Criteria
* Incapable to stay in strict decubitus position during image recording times
* Pregnant or breastfeeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles KARCHER, Pr
Role: PRINCIPAL_INVESTIGATOR
CHU de NANCY - Service de Médecine Nucléaire - France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de NANCY - Service de Médecine Nucléaire
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gilles KARCHER, Pr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A00650-45
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.